Actions
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Investor Presentation
Q2 FY27
Investor Presentation
Q1 FY27
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Healthcare Equipment & Supplies
Medical Equipment & Supplies
607 Cr
Low Risk
17.1
60.5
1.8
1.4
257.10
115.25
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
2
Neutral
7
Bullish
5
Bearish
20
Neutral
7
Bullish
19
Bearish
18
Neutral
0
Bullish
14
Bearish
18
Neutral
0
Bullish
14
Bearish
18
Neutral
0
Bullish
14
Bearish
18
Neutral
0
Bullish
14
Fabtech Technologies Ltd (FABTECH) is currently trading at 136.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Fabtech Technologies Limited is a turnkey engineering solutions provider for pharmaceutical, healthcare, and biotechnology facilities, integrating design, engineering, procurement, manufacturing, installation, commissioning, and validation of process, air, water, cleanroom, HVAC, MEP, and utility systems. The company delivered a sharp sequential recovery in Q2 FY27: revenue increased 22.8% to INR 92.09 crore, EBITDA more than doubled to INR 15.57 crore, and adjusted PAT nearly doubled to INR 8.45 crore. The improvement reflected stronger project execution, operating leverage, and better absorption of the cost base. Fabtech Technologies Limited operates across more than 62 countries, with over 2,000 installations and 500-plus designed-and-built projects. Its differentiation lies in combining local execution teams, in-house engineering and validation, selected manufacturing, and single-point accountability for complex regulated facilities. The company enters H2 FY27 with an order book above INR 900 crore and a stated INR 800-850 crore conversion opportunity over twelve months. However, achieving 25-30% growth depends on accelerated second-half execution, while revenue remains lumpy and collections, freight, raw-material costs, and geopolitical conditions remain important variables. Management is extending Fabtech's addressable market into cell and gene therapy, high-technology facilities, data centres, non-pharmaceutical infrastructure, and pre-engineered buildings. The European acquisition under evaluation could add manufacturing capability, references, employees, and credibility, although timing, approvals, valuation, and earnings accretion remain uncertain.
Over the past 52 weeks, Fabtech Technologies Ltd has traded between a low of ₹115.25 and a high of ₹257.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Fabtech Technologies Ltd has a market capitalization of approximately 607.20. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Fabtech Technologies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.05 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 607.20 Cr, Fabtech Technologies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Fabtech Technologies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Fabtech Technologies Ltd is 17.05. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Fabtech reported Rs 235 crore of gross receivables at September end. After expected credit loss provisioning, the net receivables balance was about Rs 226 crore.
Fabtech said the transaction is intended to bring European manufacturing capability, a wider product profile, employees and established market references. Management did not identify the target company or disclose a transaction value. It said a new European office alone would not provide the same operating platform.
Fabtech says the target is supported by its Rs 900 crore order book and approximately Rs 700 crore of commercially cleared work. Management also said work-in-progress material equal to about 30% of its H2 target was already ready. It expects project milestones to be weighted towards the second half.
Fabtech Technologies scheduled its post-earnings conference call for October 30, 2026, at 2:00 p.m. The call followed the release of unaudited results for the quarter and half-year ended September 30, 2026.